TQ Quiz | Navigating Neuropathies: Opening the Vault of Optic Nerve Diseases (Nashville 2025) by Events@optometricedu.com | Oct 22, 2025 | 2025 Nashville, TQ Courses | 0 comments "*" indicates required fields This field is hidden when viewing the formDate (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent 90 days past date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date Difference (Hidden)1. What term refers to edema of the optic disc, specifically resulting from elevated intracranial pressure?* A - Papilledema B - Optic atrophy C - Infectious optic neuropathy D - Optic disc drusen 2. In papilledema, what parts of the optic nerve are affected first?* A - Nasal and temporal B - Superior and temporal C - Superior and inferior D - Nasal and inferior 3. What is an early visual field defect in papilledema?* A - Nasal step B - Peripheral constriction C - Enlarged blind spot D - Arcuate defect 4. What is a late visual field defect in papilledema?* A - Nasal step B - Peripheral constriction and arcuate defect C - Enlarged blind spot D - Hemianopsia 5. Which of the following is not a typical symptom of papilledema?* A - Headache B - Transient visual obscurations C - Horizontal diplopia D - Eye pain 6. How many types of papilledema are recognized?* A - One B - Two C - Three D - Four 7. Which of the following is not a typical sign associated with papilledema?* A - Obliteration of optic cup B - Hemorrhages C - Presence of spontaneous venous pulsation (SVP) D - Paton’s folds 8. In diagnosing pseudotumor cerebri (PTC) in adults, what must the opening lumbar pressure typically be above?* A - 150 mm B - 180 mm C - 200 mm D - 250 mm 9. How many parts of the optic nerve exist to be properly neuroimaged?* A - One B - Two C - Three D - Four 10. Which of the following medications is not used to manage pseudotumor cerebri?* A - Acetazolamide B - Furosemide C - Blephamide D - Zonisamide 11. What surgical procedure is recommended to reduce morbidity in patients with severe vision loss from pseudotumor cerebri?* A - Optic nerve sheath decompression B - Trabeculectomy C - Phacoemulsification D - Ahmed drainage implant 12. What condition presents with a hyperemic swollen disc and a disc at risk?* A - Papilledema B - Non-arteritic anterior ischemic neuropathy (NAAION) C - Arteritic anterior ischemic optic neuropathy (AAION) D - Infiltrative optic neuropathy 13. What symptom is present in 90% of patients with giant cell arteritis and arteritic anterior ischemic optic neuropathy?* A - Jaw claudication B - Weight loss C - Arthralgia D - Headache 14. What is the most common acute optic neuropathy (and overall, most common after glaucoma)?* A - Arteritic anterior ischemic optic neuropathy (AAION) B - Optic neuritis C - Non-arteritis anterior ischemic optic neuropathy (NAAION) D - Papilledema 15. Which blood test is least helpful in diagnosing giant cell arteritis and arteritic anterior ischemic optic neuropathy?* A - Hemoglobin A1C B - Erythrocyte sedimentation rate C - Platelet count D - C-Reactive Protein 16. Which of the following is a steroid-sparing medication used in treating giant cell arteritis and arteritic anterior ischemic optic neuropathy?* A - Tapezza (teprotumumab) B - Actemra (tocilizumab) C - Humira (adalimumab) D - Ozempic (semaglutide) 17. What percentage of acute demyelination optic neuritis is caused by multiple sclerosis (MS)?* A - 90% B - 100% C - 50% D - 10% 18. What is the typical racial demographic for a patient with demyelinating optic neuritis from multiple sclerosis?* A - African descent B - Asian descent C - Caucasian descent D - Indo-pacific descent 19. For patient with optic neuritis in the Optic Neuritis Treatment Trial (ONTT), of those that had a normal MRI at baseline and no clinical definite multiple sclerosis (CDMS) at 10 years, what would the risk be of developing multiple sclerosis at 15 years?* A - 2% B - 17% C - 32% D - 57% 20. What condition involves optic neuritis and transverse myelitis?* A - Multiple sclerosis B - Myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) C - Neuromyelitis Optica Syndrome Disorder (NMOSD) D - Infectious optic neuropathy Personal InformationName* First Last Email* Phone*OE Tracker #License #Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional CodeNashville 2025 - Navigating Neuropathies: Opening the Vault of Optic Nerve Diseases*After 90 days, pricing will increase to $30. Price: Retake Discount Price: Promotional Discount Price: Credit Card* This field is hidden when viewing the formCourse Information (HIDDEN)This field is hidden when viewing the formCourse Name (HIDDEN)This field is hidden when viewing the formRetake Code (HIDDEN)This field is hidden when viewing the formQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/)This field is hidden when viewing the formCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
